- Broaddus, V Courtney;
- Busacca, S;
- Chacko, AD;
- Klabatsa, A;
- Arthur, K;
- Sheaff, M;
- Gunasekharan, VK;
- Gorski, JJ;
- El-Tanani, M;
- Broaddus, VC;
- Gaudino, G
Based on promising preclinical efficacy associated with the 20S proteasome inhibitor bortezomib in malignant pleural mesothelioma (MPM), two phase II clinical trials have been initiated (EORTC 08052 and ICORG 05-10). However, the potential mechanisms under
